HomeCompareNTUS vs EQR

NTUS vs EQR: Dividend Comparison 2026

NTUS yields 6.07% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $10.6K in total portfolio value· pulled ahead in Year 3
10 years
NTUS
NTUS
● Live price
6.07%
Share price
$32.96
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.9K
Annual income
$893.24
Full NTUS calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — NTUS vs EQR

📍 EQR pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNTUSEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NTUS + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NTUS pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NTUS
Annual income on $10K today (after 15% tax)
$515.78/yr
After 10yr DRIP, annual income (after tax)
$759.25/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, EQR beats the other by $2,487.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NTUS + EQR for your $10,000?

NTUS: 50%EQR: 50%
100% EQR50/50100% NTUS
Portfolio after 10yr
$35.2K
Annual income
$2,356.42/yr
Blended yield
6.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

NTUS
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NTUS buys
0
EQR buys
0
No recent congressional trades found for NTUS or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNTUSEQR
Forward yield6.07%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$29.9K$40.5K
Annual income after 10y$893.24$3,819.61
Total dividends collected$7.5K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: NTUS vs EQR ($10,000, DRIP)

YearNTUS PortfolioNTUS Income/yrEQR PortfolioEQR Income/yrGap
1$11,307$606.80$11,248$547.57+$59.00NTUS
2$12,739$641.21$12,701$666.53+$38.00NTUS
3← crossover$14,306$675.19$14,405$814.59$99.00EQR
4$16,017$708.64$16,413$999.84$396.00EQR
5$17,879$741.44$18,795$1,232.92$916.00EQR
6$19,904$773.52$21,639$1,527.95$1.7KEQR
7$22,102$804.79$25,057$1,903.80$3.0KEQR
8$24,485$835.20$29,197$2,385.87$4.7KEQR
9$27,063$864.70$34,250$3,008.70$7.2KEQR
10$29,851$893.24$40,467$3,819.61$10.6KEQR

NTUS vs EQR: Complete Analysis 2026

NTUSStock

Natus Medical Incorporated provides medical device solutions focuses on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and technologies used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing assessment, screening, and instrument fitting solutions; jaundice management products; brain injury products; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. Additionally, it offers essential products used in the everyday operation of neonatal intensive care unit (NICU); balance assessment systems to evaluate patients with balance disorders; and NICVIEW, a live streaming video for families with babies in the NICU. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation for hearing and balance care professionals. It serves university medical centers, public and private hospitals, physician offices, clinics, research laboratories, and others. The company was formerly known as ALGOTEK Instruments, Inc. and changed its name to Natus Medical Incorporated in September 1988. Natus Medical Incorporated was incorporated in 1987 and is headquartered in Middleton, Wisconsin.

Full NTUS Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this NTUS vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NTUS vs SCHDNTUS vs JEPINTUS vs ONTUS vs KONTUS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.